Physiological monitoring in wearables has expanded rapidly, but blood pressure and heart-rate sensing now represent two of the most scrutinized technologies for regulators. As devices transition from lifestyle tools to clinical-grade solutions, development teams must demonstrate performance that meets rigorous standards such as ISO 81060-2 , ISO 81060-7, ISO 81060-3 and ISO 14155 .  Parameters Research Laboratory (PRL) supports developers navigating this shift by delivering

A Familiar Framework with Important Regulatory Implications   In January 2026, the FDA released a draft guidance titled “ Cuffless Non-Invasive Blood Pressure Measuring Devices – Clinical Performance Testing and Evaluation .” The document outlines FDA’s current recommendations on how cuffless blood pressure (BP) devices—both intermittent and continuous—should be clinically evaluated to support premarket submissions.  For developers already working in this space, the guidance

When planning a clinical research study intended to support an FDA submission , sponsors often encounter terms such as multi-site, multi-investigator , and single-site, multiple-location . While these models may appear operationally similar, they differ in oversight structure, execution, and how evidence is evaluated by the FDA—particularly for cuffless blood pressure devices . Understanding these distinctions is essential for aligning trial design with FDA expectations and w

Engineering Reliability: What CTOs Need to Know About Regulatory-Grade Physiological Monitoring Validation   CTOs in medical-device startups face an engineering challenge that extends far beyond hardware and firmware. The success of a physiological monitoring product—whether a pulse oximeter, blood pressure monitor, or wearable sensing platform—depends on rigorous clinical research studies capable of supporting FDA and CE mark submissions. The gap between early engineering va

Introduction: The Importance of Clarity in Blood Pressure Device and Software Classification   As wearable technology advances, more devices are integrating blood pressure features—from clinical-grade monitors to smartwatches that “notify” users of potential changes. But not all blood pressure devices are created—or regulated—the same.  Understanding the difference between a blood pressure measurement device (FDA product code DXN) and a hypertension machine learning-based no

On September 16, 2025, the FDA issued a safety communication  warning consumers and healthcare providers about the risks of using unauthorized devices that claim to blood pressure, including certain smartwatch and smart ring features. The agency emphasized that devices without FDA marketing authorization have not been evaluated for safety or effectiveness—leaving users vulnerable to inaccurate readings and potentially harmful health decisions.  While this warning highlights t

A recent JAMA survey  revealed that many U.S. adults lack key knowledge about hypertension, including the correct threshold for diagnosis and the importance of regular monitoring. Despite widespread awareness of prevention strategies such as diet and exercise, fewer than one-quarter of people with hypertension reported checking their blood pressure more than once a week. This knowledge-behavior gap underscores the need for better tools to support both awareness and action.  K

At Parameters Research Laboratory (PRL) , we specialize in providing regulatory-grade validation for blood pressure monitoring devices, including both traditional cuff-based devices and emerging cuffless wearables. As a dedicated blood pressure validation testing lab , we deliver the scientific rigor and regulatory alignment developers need to succeed in FDA and CE mark submissions.    Why Blood Pressure Validation Matters   Accuracy in blood pressure monitoring is critical

Blood Pressure Monitoring: A Clinical Cornerstone   Blood pressure measurement is one of the most common clinical assessments, shaping decisions in nearly every healthcare setting. However, not all blood pressure monitors provide the accuracy needed for safe clinical use. FDA-approved devices  stand apart by meeting strict accuracy standards backed by international validation protocols  and clinical research studies .  In the United States, most blood pressure monitors aren’t

Setting the Standard in Clinical Research   Medical device and wearable technology developers face increasing demands for regulatory-grade clinical research studies . To achieve timely FDA and CE mark approvals, sponsors need a partner who combines scientific rigor with operational agility. Parameters Research Laboratory (PRL) provides that advantage. From Good Clinical Practice (GCP) compliance  to standards leadership and inclusive recruitment, Parameters Research Lab (PRL)

Why Arterial Line Monitoring Matters in Research   When evaluating new medical devices—particularly those designed for physiological monitoring , such as blood pressure devices or pulse oximeters, researchers need an accurate reference standard. In many cases, arterial line monitoring  serves as that standard. By providing continuous, beat-to-beat measurement of arterial blood pressure, arterial lines offer unparalleled accuracy compared to noninvasive methods. This makes the

Introduction   Cuffless blood pressure (BP) monitoring has become a major focus in wearable and medical device innovation. Unlike...

Introduction The emergence of cuffless blood pressure (BP) monitors has opened new frontiers in cardiovascular and metabolic health monitoring. These wearable and often continuous monitoring systems promise to transform hypertension management and preventive care by offering convenience, real-time data, and better patient adherence. However, without rigorous clinical validation, these innovations cannot achieve regulatory clearance—or clinical trust. Unlike traditional cuff-b